

## Recombinant Human IL18BP Protein (Fc Tag)

**Catalog Number:** PKSH032626

**Note:** Centrifuge before opening to ensure complete recovery of vial contents.


### Description

<b>Species</b>	Human
<b>Source</b>	HEK293 Cells-derived Human IL18BP protein Thr31-Gly194, with an C-terminal Fc
<b>Calculated MW</b>	44.8 kDa
<b>Observed MW</b>	60-75 kDa
<b>Accession</b>	O95998
<b>Bio-activity</b>	Not validated for activity

### Properties

<b>Purity</b>	> 95 % as determined by reducing SDS-PAGE.
<b>Endotoxin</b>	< 1.0 EU per µg of the protein as determined by the LAL method.
<b>Storage</b>	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80 °C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
<b>Shipping</b>	This product is provided as lyophilized powder which is shipped with ice packs.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution of PBS, pH 7.4. Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.
<b>Reconstitution</b>	Please refer to the specific buffer information in the printed manual. Please refer to the printed manual for detailed information.

### Data



> 95 % as determined by reducing SDS-PAGE.

### Background

Interleukin-18-binding protein, also known as Tadekinig-alfa and IL18BP, contains 1 Ig-like C2-type domain. IL18BP is constitutively expressed and secreted in mononuclear cells. IL18BP functions as an IL18 inhibitor. IL18BP binds to IL18, prevents the binding of IL18 to its receptor, and thus inhibits IL18-induced IFN-gamma production. It has been shown that IL18BP may be a promising molecular approach to inhibit neointimal hyperplasia and arteriosclerosis progression following coronary and peripheral angioplasty.

### For Research Use Only